Does Rallies show Form 4 insider transactions for CRDF?

Yes. Rallies tracks CRDF insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRDF research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRDF. It does not provide personalized investment advice.

CRDF (Cardiff Oncology, Inc. Common Stock) Stock Analysis - Insider Trades

Cardiff Oncology, Inc. Common Stock (CRDF) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDF trades at $1.84 with a market cap of $115.55M and a P/E ratio of -1.95. CRDF moved +4.55% today. Year to date, CRDF is -35.21%; over the trailing twelve months it is -40.07%. Its 52-week range spans $1.48 to $5.64. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces CRDF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRDF stock inside the company?

Recent CRDF insider activity includes PACE GARY W bought 275.00K, PACE GARY W bought 15.00K, Levine James E. bought 2.40K, Levine James E. bought 2.75K, and Levine James E. bought 2.56K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRDF Key Metrics

Key financial metrics for CRDF
Metric	Value
Price	$1.84
Market Cap	$115.55M
P/E Ratio	-1.95
EPS	$-0.93
Dividend Yield	0.00%
52-Week High	$5.64
52-Week Low	$1.48
Volume	0
Avg Volume	0
Revenue (TTM)	$488.00K
Net Income	$-41.44M
Gross Margin	0.00%

Recent CRDF Insider Trades

PACE GARY W bought 275.00K (~$673.75K) on Jul 30, 2025.
PACE GARY W bought 15.00K (~$36.75K) on Jul 30, 2025.
Levine James E. bought 2.40K (~$12.00K) on Dec 18, 2024.
Levine James E. bought 2.75K (~$14.91K) on Dec 17, 2024.
Levine James E. bought 2.56K (~$9.82K) on Dec 16, 2024.

Latest CRDF News

Cardiff Oncology Posts 72.2% ORR in Phase 2, Secures 30 mg Onvansertib Dose for Phase 3 — May 14, 2026
Cardiff Oncology to Unveil Interim Phase 2 CRDF-004 Onvansertib Data in RAS-mCRC — Apr 21, 2026
Cardiff Oncology Elevates Mohindru to CEO, Appoints CFO and COO with 486,650-Share Option at $1.58 — Apr 9, 2026
Cardiff Oncology Plans March 25 Webinar on Phase 2 Onvansertib mCRC Data — Mar 20, 2026
Cardiff Oncology Reports 72% ORR for Onvansertib in RAS-Mutant mCRC — Feb 26, 2026

CRDF Analyst Consensus

6 analysts cover CRDF: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.

Common questions about CRDF

Who is trading CRDF stock inside the company?: Recent CRDF insider activity includes PACE GARY W bought 275.00K, PACE GARY W bought 15.00K, Levine James E. bought 2.40K, Levine James E. bought 2.75K, and Levine James E. bought 2.56K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRDF?: Yes. Rallies tracks CRDF insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRDF research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRDF. It does not provide personalized investment advice.